DrugPatentWatch Database Preview
Details for Patent: 9,265,831
Which drugs does patent 9,265,831 protect, and when does it expire?
This patent has fourteen patent family members in fifteen countries.
Summary for Patent: 9,265,831
Title: | Formulations of bendamustine |
Abstract: | Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response ("PAR") basis as determined by high performance liquid chromatography ("HPLC") at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5.degree. C. to about 25.degree. C. |
Inventor(s): | Palepu; Nagesh R. (Southampton, PA), Buxton; Philip Christopher (Great Dunmow, GB) |
Assignee: | Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ) |
Application Number: | 14/031,879 |
Patent Claim Types: see list of patent claims | Composition; |
Drugs Protected by US Patent 9,265,831
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,265,831
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,572,797 | Formulations of bendamustine | ➤ Try a Free Trial |
8,609,707 | Formulations of bendamustine | ➤ Try a Free Trial |
9,572,796 | Formulations of bendamustine | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 9,265,831
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2787568 | ➤ Try a Free Trial | |||
Cyprus | 1118769 | ➤ Try a Free Trial | |||
Denmark | 2528602 | ➤ Try a Free Trial | |||
European Patent Office | 2528602 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |